US Patent Issued to Hanmi Pharm. on Oct. 7 for "Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia" (South Korean Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,867, issued on Oct. 7, was assigned to Hanmi Pharm. Co. Ltd. (Hwaseong-si, South Korea).

"Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia" was invented by In Hwan Bae (Hwaseong-si, South Korea), Ji Sook Kim (Hwaseong-si, South Korea), Jae Yul Choi (Hwaseong-si, South Korea) and Young Gil Ahn (Hwaseong-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acc...